FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending April 11, 2008
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan
notified the Company and the under-mentioned persons on 11 April 2008 of changes
in their interests in Ordinary share ADRs arising from an increase in their
interests under the Annual Investment Plan feature following the re-investment
of the dividend paid to shareholders on 10 April 2008 at a price of $43.84 per
ADR:-
Dr J P Garnier 596.14
Dr D Pulman 32.12
This notification relates to a transaction notified in accordance with
Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
11 April 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: April 11, 2008 By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc